Journal of Medical Economics

OCT 17, 2026 · JOURNAL ARTICLE

Healthcare resource utilization and costs of US patients with small cell lung cancer treated with second-line therapies: a retrospective real-world database study

Journal of Medical Economics

Aims To examine all-cause and myelosuppressive event (MYSPE)-related healthcare resource utilization and costs among patients with small cell lung cancer (SCLC) in the United State

OCT 7, 2026 · JOURNAL ARTICLE

Androgen receptor inhibitor double therapies in the management of metastatic castration-sensitive prostate cancer: a cost-effectiveness analysis

Journal of Medical Economics

Aims To evaluate the cost-effectiveness of darolutamide plus androgen deprivation therapy (DARO+ADT) versus enzalutamide plus ADT (ENZA+ADT) and apalutamide plus ADT (APA+ADT) as f

AUG 7, 2026 · JOURNAL ARTICLE

Cost-effectiveness of pembrolizumab as neoadjuvant therapy and in combination with standard of care (SOC) as adjuvant therapy for stage III-IVA resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC) in Switzerland.

Journal of Medical Economics

A rigorous health economic analysis based on a pivotal Phase 3 RCT (KEYNOTE-689) with clear cost-effectiveness results well below the Swiss willingness-to-pay threshold, though grounded in modelling rather than direct trial cost outcomes.

JUL 28, 2026 · JOURNAL ARTICLE

Estimating the cost-effectiveness of tumor treating fields for locally advanced pancreatic cancer patients.

Journal of Medical Economics

Cost-utility analysis of a novel cancer therapy showing incremental QALY gain with high ICER; confirms clinical benefit translates to measurable quality-of-life improvement but at costs above conventional thresholds.

JUN 8, 2026 · JOURNAL ARTICLE

A global model for symptomatic obstructive hypertrophic cardiomyopathy to assess the cost-effectiveness of mavacamten: results from a Dutch societal perspective.

Journal of Medical Economics

Model-based cost-effectiveness analysis demonstrates mavacamten meets accepted Dutch societal willingness-to-pay thresholds using established Markov modeling methods and published trial data.